IRD

#3308
Opus Genetics, Inc. - Common Stock
3.6 9 USD
-0.04%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
3.69
3.69
Intervallo Annuale
2.82
5.81
Variazione giornaliera
-4.16%
Variazione Mensile
+6.65%
Variazione di 6 mesi
-9.56%
Variazione Annuale
-0.81%
Chiusura Precedente
3.8 5
Open
3.6 9
Minimo
3.6 9
Massimo
3.6 9
Volume
59
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Opus Genetics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Opus Genetics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Opus Genetics, Inc. quarterly report, Q1 FY2026
10-Q

Opus Genetics, Inc. current report, 01 May 2006

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on May 5, 2006, regarding events occurring on May 1, 2006. The filing addresses significant changes to the Board of Directors and a material definitive agreement concerning stock options.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and executive compensation arrangements rather than financial performance.

Material Changes

  • Board Resignations: Inok Ahn and John Holaday resigned from the Board of Directors effective May 1, 2006.
  • Board Appointments: The Board elected Charles Beever, Kwang Soo Cheong, and Y. Michele Kang to fill the vacancies.
  • Committee Restructuring: Three committees were established:
    • Audit Committee: Kwang Soo Cheong (Chair), Charles Beever, Michele Kang.
    • Nominating and Corporate Governance Committee: Michele Kang (Chair), David McIntosh, Young Soon Park.
    • Compensation Committee: David McIntosh (Chair), Charles Beever, Kwang Soo Cheong.
  • Stock Option Agreement: An agreement was entered into with departing director John Holaday. Upon his resignation, all his stock options became fully vested and exercisable for a period of 10 years from the respective grant dates, deviating from the standard 30-day post-termination exercise window.

Guidance, Outlook, and Risks

The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The primary risk disclosed relates to the dilution potential or compensation expense associated with the accelerated vesting and extended exercise period granted to the departing director, John Holaday.

Investor Verification Checklist

  • Verify the total number of shares underlying the options granted to John Holaday to assess potential dilution.
  • Confirm the specific grant dates of Holaday's options to calculate the new expiration timeline.
  • Review the full text of Exhibit 10.1 (Extension of Stock Option Agreements) for additional terms or conditions.
  • Assess the impact of the new board composition on the company's strategic direction, given the backgrounds of the new directors in finance, consulting, and health IT.